A variety of GLP-1 drugs that were developed to treat Type 2 diabetes, including Novo Nordisk’s Ozempic, have secured label ...

近日，礼来公布SURPASS-CVOT 3期研究的积极结果，验证了 替尔泊肽 在 2型糖尿病 患者的心血管保护、肾脏保护等方面的临床价值。礼来方面表示，计划于今年年底前向全球监管机构递交这些数据。

一药多效！礼来重磅疗法3期试验结果亮眼礼来公司（Eli Lilly and ...

36氪获悉，7月31日，礼来公布SURPASS-CVOT 3期研究结果。这项大型心血管结局研究首次以循证方式验证了其重磅创新药物替尔泊肽在2型糖尿病患者的心血管保护、肾脏保护等方面的临床价值。

Topline results from the SURPASS-CVOT trial reveal that once-weekly tirzepatide (Mounjaro) has a cardiovascular risk profile ...

Topline results from the SURPASS-CVOT trial show that once-weekly tirzepatide has a cardiovascular risk profile similar to ...

Eli Lilly and Company (NYSE:LLY) stock fell on Thursday morning after the pharmaceutical giant’s diabetes drug Mounjaro ...

Eli Lilly's Mounjaro shows significant cardiovascular benefits in a major trial enhancing treatment options for type 2 ...

In patients with type 2 diabetes and CVD, the GIP/GLP-1 agonist was as good as the older drug, and possibly better in some ...

SURPASS-CVOT evaluated the efficacy and safety of tirzepatide compared with dulaglutide in adults with T2D and a confirmed ASCVD.

Eli Lilly (LLY) recently announced promising findings from its SURPASS-CVOT trial, revealing Mounjaro's potential benefits over Trulicity in reducing cardiovascular events. Despite these positive ...

The fast-selling GLP-1 drug matched Lilly's older medicine Trulicity in a closely watched cardiovascular outcomes trial, ...